-
Ruijin Hospital Unveils Five New Mutations in Rare Adrenal Hyperplasia Study
•
In a groundbreaking study, Ruijin Hospital’s Endocrine Department researchers identified five novel mutations in 17 alpha-Hydroxylase/17,20 Lyase Deficiency (17OHD), a rare inherited adrenal hyperplasia. The research, spanning three years and encompassing eight patients from seven families, unveiled six mutations within the CYP17A1 gene, with five being previously unreported. The D487-F489del…
-
SFDA Embraces Transparency: Regular Press Briefings and Personnel Rotations Announced
•
China’s State Food and Drug Administration (SFDA) is gearing up for a transparency overhaul, with its head, Shao Mingli, unveiling a slate of reforms aimed at bolstering public and media scrutiny. Scheduled for the latter half of 2007, the agency will initiate a series of regular press conferences, marking a…
-
China’s Western Pharmaceutical Exports Soar 23% in 2006, Led by Antibiotics
•
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) has reported a robust surge in China’s export values for Western pharmaceutical preparations in 2006. The year-on-year growth rate reached a significant 23%, with the total value amassing to US$504 million. Among the various categories,…
-
Shanghai Roche Pharmaceuticals Launches Erlotinib for Advanced Non-Small Cell Lung Cancer in China
•
Shanghai Roche Pharmaceuticals Ltd. made headlines in March with the launch of its lung cancer treatment, Erlotinib, in the Chinese market. This targeted therapy is designed for patients with advanced non-small cell lung cancer (NSCLC) that has continued to progress despite standard chemotherapy. Erlotinib’s mechanism of action involves the specific…
